TY - JOUR
T1 - Bacteriological and clinical studies on NM441
AU - Sawae, Yoshiro
AU - Okada, Kaoru
AU - Shimono, Nobuyuki
AU - Misumi, Hiroyasu
AU - Eguchi, Katsuhiko
AU - Takeda, Daisuke
AU - Niho, Yoshiyuki
AU - Inoue, Takatoshi
AU - Sumida, Ikuo
AU - Ninomiya, Kiyoshi
AU - Ishimaru, Toshiyuki
AU - Takaki, Koji
PY - 1996
Y1 - 1996
N2 - We performed bacteriological and clinical studies on NM441, a new quinolone antibiotic, with the following results. The antibacterial activities of NM394 against clinical isolates (10 species, 242 strains) were compared with those of ofloxacin (OFLX), ciprofloxacin (CPFX) and tosufloxacin (TFLX). The MIC 90s of NM394 against methicillin-sensitive Staphylococcus aureus (MSSA), methicillin resistant S. aureus (MRSA), Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter freundii, Proteus vulgaris, Escherichia coli, Enterobacter cloacae, Enterobacter aerogenes, Proteus mirabilis and Pseudomonas aeruginosa were 1.56, > 100, 50, ≤0.05, ≤0.05, ≤0.05, 0.10, 0.10, 0.10, 0.20 and 1.56μg/ml, respectively. The activities of NM394 against gram positive bacteria were less potent than those of TFLX, but almost as potent as OFLX and CPFX. The activities against gram negative bacteria were almost as potent as those of CPFX, and more potent than those of OFLX and TFLX. In particular, NM394 showed a high antibacterial activity against P. aeruginosa. NM441 was administered to a total of 22 patients, 20 cases with respiratory tract infections and 2 urinary tract infections, at a daily dose of 200~400mg for 2~21days. Clinical response was excellent in 5 cases, good in 15 and fair in 2. Side effects were observed in a total of 3 cases (13.6%), insomnia in 1, nausea · vomiting in 1 and rash in 1. Abnormal laboratory findings were observed in a total of 3 cases (13.6%), elevations of S-GOT·S-GPT·γ-GTP, S-GOT and S- GOT·S-GPT each in 1 case.
AB - We performed bacteriological and clinical studies on NM441, a new quinolone antibiotic, with the following results. The antibacterial activities of NM394 against clinical isolates (10 species, 242 strains) were compared with those of ofloxacin (OFLX), ciprofloxacin (CPFX) and tosufloxacin (TFLX). The MIC 90s of NM394 against methicillin-sensitive Staphylococcus aureus (MSSA), methicillin resistant S. aureus (MRSA), Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter freundii, Proteus vulgaris, Escherichia coli, Enterobacter cloacae, Enterobacter aerogenes, Proteus mirabilis and Pseudomonas aeruginosa were 1.56, > 100, 50, ≤0.05, ≤0.05, ≤0.05, 0.10, 0.10, 0.10, 0.20 and 1.56μg/ml, respectively. The activities of NM394 against gram positive bacteria were less potent than those of TFLX, but almost as potent as OFLX and CPFX. The activities against gram negative bacteria were almost as potent as those of CPFX, and more potent than those of OFLX and TFLX. In particular, NM394 showed a high antibacterial activity against P. aeruginosa. NM441 was administered to a total of 22 patients, 20 cases with respiratory tract infections and 2 urinary tract infections, at a daily dose of 200~400mg for 2~21days. Clinical response was excellent in 5 cases, good in 15 and fair in 2. Side effects were observed in a total of 3 cases (13.6%), insomnia in 1, nausea · vomiting in 1 and rash in 1. Abnormal laboratory findings were observed in a total of 3 cases (13.6%), elevations of S-GOT·S-GPT·γ-GTP, S-GOT and S- GOT·S-GPT each in 1 case.
UR - http://www.scopus.com/inward/record.url?scp=15844386164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=15844386164&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:15844386164
SN - 1340-7007
VL - 44
SP - 329
EP - 334
JO - Japanese Journal of Chemotherapy
JF - Japanese Journal of Chemotherapy
IS - SUPPL. 1
ER -